All News
Day 4 EULAR Report
The last day in London was exciting as both the Late-Breaking abstracts and new EULAR guidelines were presented.
Read Article
RA-ILD in the Age of Treat-to-Target: Put the Probe on the Chest
At EULAR 2026, speakers of the session “Catching Your Breath: Unravelling RA Associated Interstitial Lung Disease (ILD)” noted RA-ILD is one of the few outcomes not improving in the biologic era. Three abstracts reinforce that message and make the case for a practical, low-cost screening tool that is already in most rheumatologists’ hands.
Read Article
Treat to Target Works in Elderly Onset RA
Dr. Jiha Lee reports on abstract POS1326 at EULAR 2026 in London
https://t.co/X4vhR9KofC https://t.co/TSquFmZJCP
Dr. John Cush RheumNow ( View Tweet)
The pain that inflammation does not explain in SpA and PsA
At EULAR 2026, the NEUPIA study (OP0317), a prospective observational investigation conducted at KU Leuven and University Hospitals Leuven, provides the most detailed longitudinal characterisation to date of these https://t.co/OYMf4KKBc1
Dr. John Cush RheumNow ( View Tweet)
Can you step down #belimumab
In well controlled #SLE without flaring?
N=22 on #BEL eligible of 152
Able to taper if
REM >6/12
No #steroids
Normal C3,C4
Neg #antiDNA
Remission maintained in pts who reduced dose
6/22 didn’t flare OFF Rx
✅nice
#POS1052 #EULAR2026
@RheumNow https://t.co/IEyfRtTGfT
Links:
Janet Pope Janetbirdope ( View Tweet)
#EULAR2026 Please find my video on deep tissue depletion and associated histological remission following treatment with Obinutuzumab in #lupus nephritis @RheumNow
https://t.co/V9CNdPsLcV https://t.co/WLVFyaSSUE
Links:
Md Yuzaiful Md Yusof Yuz6Yusof ( View Tweet)
This study evaluated the risk of flares after sustained drug-free rem in SLE.
% of pts w/ reported flares w/n yrs in rem:
48.6% at 2yrs
42.3% at 3yrs
35.2% at 5 yrs
Mucocut, msk, renal & immuno - ⬆️affected domain
Reassess pts regularly.
POS1354 @RheumNow #EULAR2026 https://t.co/DG0yNOW1nh
sheila RHEUMarampa ( View Tweet)
#EULAR2026 #SARD #vaccination #recommendations
I think 🤔
✅proactive➡️take responsibility
✅close gap
✅mostly practical
But
How long will #shingrix work if #vaccine
In age<50yrs
When if ever
To revaccinate?
@RheumNow @eular_org @ACRheum https://t.co/najJwzdecL
Links:
Janet Pope Janetbirdope ( View Tweet)
Does #RA accelerate age-related functional decline in older adults? STAR study (n=421, age 55-85): RA with worse HAQ, grip strength, but aging's effect on function similar in RA vs controls. Geriatric syndromes like sarcopenia may matter more than RA @RheumNow #EULAR2026 POS0360
Jiha Lee JihaRheum ( View Tweet)
Thoracic U/S for #RA-ILD screening? Multicenter study (n=272, Argentina/Denmark/Belgium): 86% sensitivity and 94% NPV. Accessible, no radiation, integrates into clinic flow. Time to build TUS into routine RA-ILD pathways? @RheumNow #EULAR2026 POS1265 https://t.co/FGH5iUstxa
Jiha Lee JihaRheum ( View Tweet)
Think palindromic rheumatism is non-erosive? Not always. Leeds U/S cohort (n=127, 16yrs follow-up): 9.4% had low-grade erosions at baseline; 6.1% without baseline erosions developed new erosions over 53 mo. More frequent flares, more erosions. @RheumNow #EULAR2026 POS1262
Jiha Lee JihaRheum ( View Tweet)
Patient-initiated telemedicine follow-up cut rheumatology visits by 25% in stable #SpA, but not equally for everyone. Reductions were greatest in men, axSpA, bDMARD users, and the oldest patients (64+, 34% fewer visits). Patient-centered care delivery @RheumNow #EULAR2026 POS1345
Jiha Lee JihaRheum ( View Tweet)
T2T works in elderly-onset #RA. tREACH trial (n=425): EORA (mean age 73) achieve LDA similar to young-onset RA; often with lower treatment intensity when seronegative. Drug tolerability comparable in EORA vs YORA despite more comorbidities. @RheumNow #EULAR2026 POS1326 https://t.co/tKRki2KLzP
Jiha Lee JihaRheum ( View Tweet)
SELECT-Axis 2 trial and Withdrawal of Upadacitinib - Of 734 pts, 194 were in remission at wk104--> UPA w/d & 22% maintained drug-free remission for >48wks. Rest flared, median time to flare: 3.1 mos (89% regained LDA by wk24 w/ restart) #EULAR2026 #axSpA POS1350 https://t.co/7A7CAHxLxX
Dr. John Cush RheumNow ( View Tweet)
Comorbidities don’t just impact prognosis, remission and treatment in RA- they impact mortality. Comorbidities cannot be treated in a “one size fits all” approach; they should be assessed and managed on an individual basis.
@ElenaNikiUK
@RheumNow #EULAR2026 https://t.co/UmB63QBl7N
Mrinalini Dey DrMiniDey ( View Tweet)
Extended-release febuxostat (HR091506) vs standard febuxostat in gout. 442 patients, 36 weeks.
SUA <300 μmol/L at Week 36:
63.8% vs 40.7% (p<0.0001)
A 23% difference on the most stringent urate target. Well tolerated and acceptable safety profile
Abstr LB0008 @RheumNow https://t.co/PSrn7K5BVS
Antoni Chan MD (Prof) synovialjoints ( View Tweet)
Do probiotics improve disease activity in PsA?
POS0290: no
MEDISPA RCT n=66
Multispecies probiotics not superior to placebo at week 12
#EULAR2026 @RheumNow https://t.co/1byJ1nB4GF
Nelly ZIADE 🍀 Nellziade ( View Tweet)
#EULAR2026 LB0008 Phase 3 RCT in China of pts with high urate (SUA) & 2 gout flares within last year (N=142), HR091506, an extended formulation release of Febuxostat to prolong response was superior to Febuxostat at WK36. Unclear if will proceed to regulatory submission @RheumNow https://t.co/9lcVEzcxc1
Links:
Md Yuzaiful Md Yusof Yuz6Yusof ( View Tweet)
🏠 Take Home Messages from the early #axSpA session
🔺 Earlier diagnosis is possible and better
🔺 Early axSpA is not synonymous to mild
🔺 Longitudinally, early axSpA is heterogeneous
🔺 MRI has transformed the field
❗️Beware of pitfalls
#EULAR2026 @RheumNow
Nelly ZIADE 🍀 Nellziade ( View Tweet)
#EULAR2026 LB0004 First BiTE, now TriTE! Tri-specific CC312 CD19/CD3/CD28 (i.e. CD28 co-stimulates Tcell activation) showed deep Bcell depletion, early efficacy & safety in 10 #SLE patients up to 52WKs. Promising but longer FU needed to see if repeat dosing needed @RheumNow https://t.co/6Lbm9LYJrY
Links:
Md Yuzaiful Md Yusof Yuz6Yusof ( View Tweet)
